What is the minimum investment required for PCD Pharma Franchise?

The minimum investment typically ranges from ₹2–5 lakhs, depending on territory size, product selection and initial stock planning. Our team will help structure this based on your goals.

What documents are required to become a franchise partner?

You will need a valid Drug License, GST registration and basic KYC documents. Our team will guide you through every step of the documentation process.

What kind of support and training do you provide?

We provide product training, sales guidance, marketing materials, doctor coverage strategies, and ongoing business support through dedicated account managers.

How are territories allocated and protected?

Territories are allocated based on mutual agreement and market mapping. We offer genuine monopoly rights with clear documentation to avoid internal competition.

What is the expected profit margin and ROI timeline?

Average profit margins range from 25–30%, with typical ROI timelines between 12–18 months, depending on your execution and territory potential.

How do you ensure product quality and compliance?

All products are manufactured in WHO-GMP certified facilities with 100% quality testing, robust documentation and DCGI approvals as applicable.

What is the delivery timeline and process?

Dispatch timelines depend on order size and location, but we maintain a strong track record of timely delivery across India with proper packaging and logistics partners.

Tablet & Capsules

NEXTLIFE-150

Ursodeoxycholic Acid 150mg Tab

Pack: 10x10
Format: Alu-Alu

MRP₹1,960.00

A high-efficacy hepatoprotective and litholytic medication formulated for the management of cholestatic liver diseases and the dissolution of gallstones. NEXTLIFE-150 contains Ursodeoxycholic Acid (UDCA) 150mg, a naturally occurring bile acid that protects liver cells from damage and improves bile flow.

About The Product

Key Benefits

Hepatoprotective and Cytoprotective Action

Ursodeoxycholic Acid 150mg works by displacing toxic, hydrophobic bile acids that accumulate in the liver during cholestasis. By replacing these harmful acids with the non-toxic UDCA, it prevents damage to the liver cell membranes and stops the progression of liver scarring.

Dissolution of Cholesterol Gallstones

NEXTLIFE-150 reduces the secretion of cholesterol into the bile and inhibits the intestinal absorption of cholesterol. This leads to the desaturation of bile, allowing existing radiolucent gallstones to gradually dissolve and preventing the formation of new stones.

Improvement of Bile Flow

The medication acts as a choleretic agent, stimulating the flow of bile from the liver into the intestines. This helps to clear biliary sludge and relieves the symptoms associated with biliary stasis, such as itching (pruritus) and upper abdominal discomfort.

Immune Modulating Effects

UDCA has been shown to decrease the expression of abnormal immune markers on the surface of liver cells. This helps to reduce the autoimmune-mediated destruction of bile ducts in conditions like Primary Biliary Cholangitis (PBC).

Anti-Apoptotic Properties

At a cellular level, Ursodeoxycholic Acid inhibits the pathways that lead to programmed cell death (apoptosis) in hepatocytes. This protective effect is vital for maintaining liver function in patients with chronic inflammatory liver disorders.

Favorable Safety Profile

As a naturally occurring component of human bile, UDCA is well-tolerated for long-term use. The 150mg strength allows for precise, weight-based dosing schedules to ensure maximum therapeutic benefit with minimal gastrointestinal side effects.

Indication Primary Biliary Cholangitis (PBC), Dissolution of Radiolucent Gallstones, Biliary Sludge and Cholestatic Liver Disease, Chronic Hepatitis with Cholestasis, Alcoholic and Non-Alcoholic Fatty Liver Disease, Prevention of Gallstones during Rapid Weight Loss.

Indications

Primary Biliary Cholangitis (PBC)
Dissolution of Radiolucent Gallstones
Biliary Sludge and Cholestatic Liver Disease
Chronic Hepatitis with Cholestasis
Alcoholic and Non-Alcoholic Fatty Liver Disease
Prevention of Gallstones during Rapid Weight Loss.

Product descriptions, dosage forms, and compositions listed on the website are for reference by licensed practitioners and distributors only.

NEXTLIFE-150